Oncology Reimbursement Changes Could Close Small Practices, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen remains confident its oncology portfolio is on track to deliver growth despite changes in reimbursement in the market, Associate Director-Investor Relations Laura Biswas said
You may also be interested in...
CMS Extends Oncology Quality Of Care Demo
The 2006 version of the demo project is expected to require that oncologists report clinical guideline adherence, rather than assess symptoms related to patient suffering.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.